Disposition and metabolism of the colchicine derivative [14C]-ZD6126 in rat and dog

被引:5
作者
Partridge, E. A. [1 ]
D'Souza, R. A. [1 ]
Lenz, E. M. [1 ]
Smith, S. M. [1 ]
Clarkson-Jones, J. [1 ]
Roberts, D. W. [1 ]
机构
[1] Astra Zeneca, DMPK, Macclesfield SK10 4TJ, Cheshire, England
关键词
C-14]-ZD6126; vascular targeting agent; enterohepatic recirculation; colchicine derivative;
D O I
10.1080/00498250701861742
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. The tissue distribution, disposition and metabolism of ZD6126, a novel vascular targeting agent, were investigated in rat and dog. This paper comprises the findings of several investigations, including rat quantitative whole-body autoradiography (QWBA), rat and dog balance and metabolism (both in intact and bile-duct-cannulated animals), rat enterohepatic recirculation, and comparison of metabolism between young and mature rats. 2. Following intravenous administration of [C-14]-ZD6126 to rats, quantitative whole-body autoradiography showed that radioactivity was widely distributed, then rapidly eliminated from the body. 3. ZD6126-related material was eliminated primarily in the faeces (approximately 86%) of both species, indicating the importance of biliary clearance. 4. Metabolite profiles from intact and bile-duct-cannulated animals suggest that ZD6126 is cleared primarily by metabolism. In rat, the major metabolites were ZD6126 phenol, its glucuronide and other metabolites consistent with O-demethylation and conjugation. ZD6126 was more extensively metabolized by male than female rats, and also in young compared with mature rats. In dog, metabolism occurred primarily via direct glucuronidation of the active species, ZD6126 phenol. 5. Following intraduodenal infusion of bile containing [C-14]-ZD6126-related material to bile-duct-cannulated rats, 30% of the radioactivity was subsequently recovered in bile and urine, showing that one or more components in bile are reabsorbed and undergo enterohepatic recirculation.
引用
收藏
页码:399 / 421
页数:23
相关论文
共 24 条
[1]  
Blakey DC, 2002, CLIN CANCER RES, V8, P1974
[2]   ZD6126: A novel small molecule vascular targeting agent [J].
Blakey, DC ;
Ashton, SE ;
Westwood, FR ;
Walker, M ;
Ryan, AJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 54 (05) :1497-1502
[3]  
Chaplin DJ, 1999, BRIT J CANCER, V80, P57
[4]   Distribution of radioactivity and metabolite profiling in tumour and plasma following intravenous administration of a colchicine derivative (14C-ZD6126) to tumour-bearing mice [J].
D'Souza, R. A. ;
Partridge, E. A. ;
Roberts, D. W. ;
Ashton, S. ;
Ryan, A. ;
Patterson, A. B. ;
Wilson, Z. ;
Thurrell, C. C. .
XENOBIOTICA, 2007, 37 (03) :328-340
[5]  
Davis PD, 2002, CANCER RES, V62, P7247
[6]  
GADGEEL SM, 2002, P AM SOC CLIN ONCOLO, V21
[7]  
Gibson GG., 2001, Introduction to Drug Metabolism
[8]   In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug [J].
Grosios, K ;
Holwell, SE ;
McGown, AT ;
Pettit, GR ;
Bibby, MC .
BRITISH JOURNAL OF CANCER, 1999, 81 (08) :1318-1327
[9]   VINCA ALKALOIDS - ANTIVASCULAR EFFECTS IN A MURINE TUMOR [J].
HILL, SA ;
LONERGAN, SJ ;
DENEKAMP, J ;
CHAPLIN, DJ .
EUROPEAN JOURNAL OF CANCER, 1993, 29A (09) :1320-1324
[10]  
HUNTER AL, 1975, J PHARMACOL EXP THER, V192, P605